» Articles » PMID: 32571838

A Neutralizing Human Antibody Binds to the N-terminal Domain of the Spike Protein of SARS-CoV-2

Abstract

Developing therapeutics against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be guided by the distribution of epitopes, not only on the receptor binding domain (RBD) of the Spike (S) protein but also across the full Spike (S) protein. We isolated and characterized monoclonal antibodies (mAbs) from 10 convalescent COVID-19 patients. Three mAbs showed neutralizing activities against authentic SARS-CoV-2. One mAb, named 4A8, exhibits high neutralization potency against both authentic and pseudotyped SARS-CoV-2 but does not bind the RBD. We defined the epitope of 4A8 as the N-terminal domain (NTD) of the S protein by determining with cryo-eletron microscopy its structure in complex with the S protein to an overall resolution of 3.1 angstroms and local resolution of 3.3 angstroms for the 4A8-NTD interface. This points to the NTD as a promising target for therapeutic mAbs against COVID-19.

Citing Articles

NIEAs elicited by wild-type SARS-CoV-2 primary infection fail to enhance the infectivity of Omicron variants.

Gui Q, Wang H, Liu C, Li W, Zhou B, Tang S Virol J. 2025; 22(1):45.

PMID: 39994733 PMC: 11849304. DOI: 10.1186/s12985-025-02667-0.


Antibody-dependent enhancement of coronaviruses.

Tao T, Tian L, Ke J, Zhang C, Li M, Xu X Int J Biol Sci. 2025; 21(4):1686-1704.

PMID: 39990674 PMC: 11844293. DOI: 10.7150/ijbs.96112.


Avian Antibodies as Potential Therapeutic Tools.

Eriksson M, Larsson A Antibodies (Basel). 2025; 14(1).

PMID: 39982233 PMC: 11843883. DOI: 10.3390/antib14010018.


Structural prediction of chimeric immunogen candidates to elicit targeted antibodies against betacoronaviruses.

Simpson J, Kasson P PLoS Comput Biol. 2025; 21(2):e1012812.

PMID: 39908344 PMC: 11809852. DOI: 10.1371/journal.pcbi.1012812.


Reverse mutational scanning of SARS-CoV-2 spike BA.2.86 identifies epitopes contributing to immune escape from polyclonal sera.

Bdeir N, Luddecke T, Maass H, Schmelz S, Rand U, Jacobsen H Nat Commun. 2025; 16(1):809.

PMID: 39827186 PMC: 11743207. DOI: 10.1038/s41467-025-55871-5.


References
1.
Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

2.
Dimitrov D . The secret life of ACE2 as a receptor for the SARS virus. Cell. 2003; 115(6):652-3. PMC: 7133233. DOI: 10.1016/s0092-8674(03)00976-0. View

3.
Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H . Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020; 581(7807):221-224. PMC: 7328981. DOI: 10.1038/s41586-020-2179-y. View

4.
Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X . Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020; 584(7819):115-119. DOI: 10.1038/s41586-020-2380-z. View

5.
Chen X, Li R, Pan Z, Qian C, Yang Y, You R . Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020; 17(6):647-649. PMC: 7167496. DOI: 10.1038/s41423-020-0426-7. View